OncRef

Clinical Trial: NCT04742959

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:TransThera Sciences (Nanjing), Inc.
Information Provided By:TransThera Sciences (Nanjing), Inc.
Last Update Posted:2024-04-26

Study Overview

Brief Summary

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

Official Title

A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors

Conditions

Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer

Intervention / Treatment

  • Drug: TT-00420
  • Combination Product: Nab-Paclitaxel

Other Study ID Numbers

  • TT420X1103

Start Date (Actual)

2021-03-14

Primary Completion Date (Actual)

2024-02-20

Study Completion Date (Actual)

2024-02-20

Enrollment (Actual)

203

Study Type

Interventional

Phase

Phase 1, Phase 2